CIK细胞免疫治疗原发性肝癌的临床疗效评价  

Clinical evaluation of CIK cell immunotherapy for primary hepatocellular carcinoma

作　　者：孙英慧 宋爽 杨紫恩 Sun Yinghui;Song Shuang;Yang Zien(General Hospital of Northem War Zone, Shenyang,Liaoning 110016, China)

机构地区：[1]北部战区总医院,辽宁沈阳110016

出　　处：《医药前沿》2019年第19期36-37,共2页Journal of Frontiers of Medicine

摘　　要：目的:评价CIK细胞免疫治疗原发性肝癌的临床疗效.方法:选取我院2010年5月-2016年5月收治的71例原发性肝癌患者,所有患者均行CIK细胞续灌输入治疗,观察治疗后患者的临床疗效.结果:患者治疗后T细胞亚群CD8+水平以及CD4^+/CD8^+较治疗前有所改善,差异有统计学意义(P<0.05),治疗前后CD3^+、CD4^+水平差异无统计学意义(P>0.05),治疗后患者的免疫功能有明显改善.随访期内71例患者复发率和死亡率分别为18.3%和12.6%.结论:CIK细胞免疫治疗原发性肝癌的临床疗效较好,对于改善患者免疫功能具有积极作用,可在临床应用.Objective To evaluate the clinical efficacy of CIK cell immunotherapy for primary hepatocellular carcinoma. Methods 71 patients with primary hepatocellular carcinoma admitted to our hospital from May 2010-May 2016 were selected. All patients were treated with CIK cell infusion. The clinical efficacy was observed after treatment Results After treatment, the levels of CD8^+ and CD4^+/ CD8^+ in T lymphocyte subsets were improved compared with those before treatment, with statistical significance (P < 0.05). There was no significant difference in the levels of CD3^+ and CD4^+ before and after treatment (P > 0.05). After treatment, the immune function of patients was improved significantly. During the follow-up period, the recurrence rate and mortality rate of 71 patients were 18.3% and 12.6%, respectively;Conclusion CIK cell immunotherapy is effective in the treatment of primary hepatocellular carcinoma, and has a positive effect on improving the immune function of patients. It can be widely used in clinic.

关 键 词：原发性肝癌 细胞免疫治疗 CIK细胞 免疫功能 临床疗效 

分 类 号：R730.5[医药卫生—肿瘤]